USpolicy

News

Amgen and AstraZeneca's fast-growing asthma drug Tezspire is now poised to take on rival Dupixent in chronic rhinosinusitis with nasal polyps.

News

Job losses start at federal agencies, including HHS, but initial reports suggest some workers who have been let go are quickly being reinstated.

News

AstraZeneca has become the second pharma group to reach an agreement with the Trump administration on Most Favoured Nation (MFN) drug pricing.

Market Access

Two pharmaceutical giants have paused investment in the UK. More than a setback for British life sciences, it’s a warning sign for the future.

News

The first stage of AstraZeneca's promised $50 billion investment in US facilities is underway as it breaks ground on a facility in Virginia.

News

Possible implications of TrumpRx, the federal direct-to-consumer sales channel, are starting to emerge ahead of its scheduled launch next year.